---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-26-000028"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:21:10.745518+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics Phase 2 LOTUS trial meets primary endpoint; HiSCR75 rates 42.2% and 42.9% for abdakibart in HS

## Summary
- Abdakibart 150 mg achieved 42.2% HiSCR75 (p=0.018), 300 mg achieved 42.9% (p=0.015); placebo 25.6%.
- Statistically significant benefit on secondary endpoints HiSCR50, change in IHS4, and draining tunnel count.
- Abdakibart well tolerated; most TEAEs mild to moderate, no neutropenia, serious infections, or opportunistic infections.
- Response similar in patients with and without prior biologic exposure.
- Avalo plans to advance abdakibart into a registrational Phase 3 program.

## SEC filing metadata
- accession: 0001534120-26-000028
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000028/0001534120-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412026000028/avtx-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-26-000028
- JSON: https://secwatch.observer/filing/0001534120-26-000028.json
- Plain text: https://secwatch.observer/filing/0001534120-26-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.